Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

10 results
Display

Inhibiting NF-kappaB Activation by Triptolide Enhances TRAIL-induced Cell Death in Lung Cancer Cells

Kim YS, Park JS, Jee YK, Lee KY

  • KMID: 2200197
  • J Lung Cancer.
  • 2003 Mar;2(1):61-68.
PURPOSE: High frequency of p53 mutations in lung cancer is a major obstacle to chemotherapy-induced apoptosis because p53 is known to play an important role as a final translator for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Relationship between Tumor Angiogenesis and Micrometastases in The Regional Lymph Nodes of Patient with Stage I Non-Small Cell Lung Cancer

Roh MS, Lee JI, Choi PJ

  • KMID: 2200196
  • J Lung Cancer.
  • 2003 Mar;2(1):54-60.
PURPOSE: This study was performed to evaluate the relation between nodal micrometastasis and tumor angiogenesis, and to assess potential molecular markers pertaining to the development of nodal micrometastasis. MATERIALS AND...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Polymorphisms in ERCC1 and ERCC2/XPD and Survival in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin Based Chemotherapy

Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Cho JH, Lee HL, Hwang TS

  • KMID: 2200195
  • J Lung Cancer.
  • 2003 Mar;2(1):44-53.
PURPOSE: The expressions of low levels of ERCC1 (excision repair crosscomplementation group 1) and ERCC2/XPD (excision repair cross- complementation group 2) have been studied in order to find a potential...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of Topotecan as a Second-Line Treatment of Small-Cell Lung Cancer in Patients with Refractory and Sensitive Disease: Retrospective Study

Park HS, Kim MH, Lee YS, Ahn JY, Kwan SJ, Lee KS, Kang DW, Jung SS, Kim JO, Kim SY

  • KMID: 2200194
  • J Lung Cancer.
  • 2003 Mar;2(1):37-43.
PURPOSE: Chemotherapy is the treatment of choice for small-cell lung cancer (SCLC). Despite the high response rates with first-line therapy, most patients eventually experience disease progression, and finally become candidates...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lack of the Difference in Outcome between N2 and N3 Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy; A Retrospective Analysis of 186 Patients

Kim YS, Lee SW, Choi EK, Kim JH, Ahn SD, Shin SS, Lee JS, Suh C, Kim SW, Kim DS, Kim WS, Lee SD

  • KMID: 2200193
  • J Lung Cancer.
  • 2003 Mar;2(1):31-36.
PURPOSE: To evaluate the difference in the patterns of failure and treatment for the outcomes of concurrent chemoradiotherapy, between clinical stage N2 and N3, in locally advanced unresectable stage III...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Phase II Study of 3-D Conformal Radiotherapy and Concurrent MVP (Mitomycin-C+Vinblastine+Cisplatin) Chemotherapy for Unresectable Non-Small Cell Lung Cancer

Yoon SM, Choi EK, Lee SW, Lee JS, Lee SD, Suh C, Kim SW, Kim WS, Ahn SD, Yi BY, Kim JH, Shin SS, Koh Y, Kim DS, Kim WD

  • KMID: 2200192
  • J Lung Cancer.
  • 2003 Mar;2(1):23-30.
PURPOSE: To evaluate the feasibility, treatment outcome, and toxicity of hyperfractionated 3-D conformal radiotherapy and concurrent MVP chemotherapy in locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). MATERIALS...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Response of Docetaxel Plus Cisplatin and Paclitaxel Plus Carboplatin Chemotherpy in Non-Small Cell Lung Cancer

Cho GJ, Ju JY, Park KH, Son CY, Wi JO, Kim KS, Kim YI, Lim SC, Kim YC, Park KO

  • KMID: 2200191
  • J Lung Cancer.
  • 2003 Mar;2(1):16-22.
PURPOSE: Almost 80% of primary lung cancers are non-small cell lung cancer (NSCLC), and their prognosis is very poor since only one-fourth of patients with NSCLC present with a resectable...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Molecular Aspects of Radiotherapy

Park HJ

  • KMID: 2200190
  • J Lung Cancer.
  • 2003 Mar;2(1):10-15.
When tumor cells are exposed to ionizing radiation, various and complicated molecular biological changes take place leading to cell death, mutation, and recovery from sublethal damage. It has been known...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adjuvant Chemotherapy for Completely Resected Non-Small Cell Lung Cancer

Kim SW

  • KMID: 2200189
  • J Lung Cancer.
  • 2003 Mar;2(1):6-9.
Lung cancer is the number one cause of cancer-related deaths in Korea. Nonsmall cell lung cancers account for about 80% of these cases. Because the long term survival of patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Screening for Lung Cancer with Low-Dose Computed Tomography

Goo JM

  • KMID: 2200188
  • J Lung Cancer.
  • 2003 Mar;2(1):1-5.
Lung cancer is the leading cause of cancer deaths in Korea. It is hoped that the screening for lung cancer will reduce the mortality from these kinds of tumors, which...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr